Sanofi knows the pharma world is wondering what happens next, what with former CEO Chris Viehbacher riding off into the sunset. That's why Chairman and acting CEO Serge Weinberg is giving interviews these days. And according to his latest with Handelsblatt, the French drugmaker is shopping for deals in some steady-but-slower fields.
Mylan is charging full speed ahead with its $5.3 billion acquisition of Abbott Laboratories' overseas generics business. The drugmaker will shell out $32.5 million to 5 of its top executives ahead of schedule to avoid a tax penalty meant to discourage companies from shifting their domicile abroad.
Established medical diagnostic device company Welch Allyn has bought up all the assets of telehealth startup HealthInterlink in its first foray into remote patient vital sign monitoring. Welch Allyn sees this as an early step in investing in post-acute care monitoring outside of a hospital setting.
After serial acquirer Valeant lost a months-long takeover battle for Allergan, many industry-watchers expected the company to restore its dealmaking reputation with another quick pickup. But the Canadian pharma may be heading in the opposite direction.
Merck may have to rethink its math on the Cubist buyout. Announcing the $9.5 billion transaction Monday, the company pointed to an earnings bump beginning in 2016. But later in the day, a U.S. court nixed all but one of the patents covering its top seller, Cubicin--and that patent expires in 2016.
Luxembourg-based Eurofins Scientific agreed to buy Boston Heart Diagnostics, an advanced diagnostics provider, for $140 million, the company said.
Symmetry Medical's OEM Solutions business was acquired by Tecomet.
Merck is shelling out $9.5 billion for antibiotics specialist Cubist Pharmaceuticals, joining the wave of major drugmakers with a renewed interest in anti-invectives.
Merck & Co. is betting almost $10 billion on beefing up its antibiotics business. The U.S. drugmaker said it agreed to buy Cubist Pharmaceuticals for $102 per share, or about $8.4 billion, plus $1.1 billion in net debt, for a total transaction value of $9.5 billion. The buyout is part of Merck's plan to zero in on its most promising businesses and scale back the rest.
With a months-long hostile pursuit from Valeant and failed talks to buy North Carolina's Salix, Allergan had already been on an M&A roller coaster this year before finally agreeing to sell itself to Actavis last month. And options traders, for one, are afraid the ride's not over yet.